ChromaDex reports record Q4 net sales $29.1M (+37% YoY); first full-year net income $8.6M

Niagen Bioscience, Inc.

Full-year net sales $99.6M (+19% YoY); Tru Niagen sales $76.8M (+10%), Niagen ingredients $19.2M (+82%).
Q4 net income $7.2M vs $0.1M a year ago; full-year net income $8.6M vs net loss $4.9M in 2023.
Adjusted EBITDA $8.5M in 2024; operating cash flow $12.1M; cash $44.7M with no debt.
G&A expense dropped $6.6M for the year due to $3.5M royalty reversal and $1.3M legal settlement recovery.
FDA granted Orphan Drug and Rare Pediatric Disease Designations for NR; Niagen Plus now at 475+ clinics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.